However, despite the loss of p53 function, the NIH-OVCAR3 cells were resistant to VE-821 and this resistance was not due to inadequate ATR inhibition, which was consistent with that observed in other ovarian cancer cell lines. This evidence concerns the gene TP53 and ovarian carcinoma.